Rigel Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Rigel Pharmaceuticals' es Raul Rodriguez , nombrado en May 2010, tiene una permanencia de 13.92 años. compensación anual total es $3.44M, compuesta por 21.2% salario y 78.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.75% de las acciones de la empresa, por valor de $1.44M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 6.5 años, respectivamente.
Información clave
Raul Rodriguez
Chief Executive Officer (CEO)
US$3.4m
Compensación total
Porcentaje del salario del CEO | 21.2% |
Permanencia del CEO | 14yrs |
Participación del CEO | 0.7% |
Permanencia media de la dirección | 3yrs |
Promedio de permanencia en la Junta Directiva | 6.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding
May 01Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Mar 04Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
Feb 23Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S
Jan 15Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?
Oct 25Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib
Oct 10Rigel Pharma adds ~7% to reach over two month high
Aug 18Rigel rises 17% on strong Q2 result
Aug 03Rigel Pharmaceuticals: A Status Check
May 31Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Apr 21Rigel Pharmaceuticals: Why The Stock Is On A Run
Mar 21What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates
Mar 06Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net
Feb 01An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued
Jan 14Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive
Nov 30Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?
Nov 02Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines
Sep 06It's Unlikely That Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Will See A Huge Pay Rise This Year
May 12Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$20m |
Dec 31 2023 | US$3m | US$728k | -US$25m |
Sep 30 2023 | n/a | n/a | -US$24m |
Jun 30 2023 | n/a | n/a | -US$38m |
Mar 31 2023 | n/a | n/a | -US$45m |
Dec 31 2022 | US$3m | US$700k | -US$59m |
Sep 30 2022 | n/a | n/a | -US$83m |
Jun 30 2022 | n/a | n/a | -US$85m |
Mar 31 2022 | n/a | n/a | -US$85m |
Dec 31 2021 | US$3m | US$662k | -US$18m |
Sep 30 2021 | n/a | n/a | -US$15m |
Jun 30 2021 | n/a | n/a | -US$8m |
Mar 31 2021 | n/a | n/a | -US$11m |
Dec 31 2020 | US$3m | US$662k | -US$30m |
Sep 30 2020 | n/a | n/a | -US$28m |
Jun 30 2020 | n/a | n/a | -US$25m |
Mar 31 2020 | n/a | n/a | -US$28m |
Dec 31 2019 | US$3m | US$649k | -US$67m |
Sep 30 2019 | n/a | n/a | -US$46m |
Jun 30 2019 | n/a | n/a | -US$59m |
Mar 31 2019 | n/a | n/a | -US$64m |
Dec 31 2018 | US$4m | US$637k | -US$70m |
Sep 30 2018 | n/a | n/a | -US$100m |
Jun 30 2018 | n/a | n/a | -US$93m |
Mar 31 2018 | n/a | n/a | -US$87m |
Dec 31 2017 | US$2m | US$618k | -US$78m |
Compensación vs. Mercado: La compensación total de Raul($USD3.44M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.60M).
Compensación vs. Ingresos: La compensación de Raul ha aumentado mientras la empresa no es rentable.
CEO
Raul Rodriguez (62 yo)
14yrs
Permanencia
US$3,440,790
Compensación
Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 14yrs | US$3.44m | 0.75% $ 1.2m | |
Executive VP & CFO | 6yrs | US$1.21m | 0.069% $ 110.4k | |
Executive VP | 1.4yrs | US$683.00k | 0.0029% $ 4.5k | |
Executive VP & Chief Commercial Officer | 3.8yrs | US$1.34m | 0.031% $ 50.0k | |
Senior VP of Human Resources | 2.3yrs | sin datos | sin datos | |
Executive Vice President of Research | 7.7yrs | US$796.09k | sin datos | |
Executive VP & Chief Business Officer | less than a year | sin datos | sin datos | |
Executive VP & Chief Medical Officer | less than a year | sin datos | sin datos | |
Vice President of Marketing | no data | sin datos | sin datos |
3.0yrs
Permanencia media
60yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RIGL se considera experimentado (3 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 9.5yrs | US$3.44m | 0.75% $ 1.2m | |
Independent Director | 27.2yrs | US$138.58k | 0.030% $ 47.4k | |
Independent Director | 6.8yrs | US$138.58k | 0.029% $ 45.4k | |
Independent Director | 5.2yrs | US$145.58k | 0.029% $ 45.4k | |
Independent Chairman of the Board | 6.5yrs | US$190.58k | 0.029% $ 45.4k | |
Independent Director | 2.4yrs | US$140.58k | 0.011% $ 17.0k | |
Independent Director | 3yrs | US$212.98k | 0.018% $ 28.4k |
6.5yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de RIGL se considera experimentada (6.5 años de antigüedad promedio).